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Abstract 
 Alcohol use disorders (AUDs) affect approximately 13.9% of the population in the 
United States. AUDs result from a combination of biological and environmental factors, 
and have a strong genetic component with heritability rates estimated to be 50-60%. 
Alcohol consumption has been shown to enhance GABAA receptor activity, and genetic 
studies have shown an association between AUDs and single nucleotide 
polymorphisms (SNPs) within GABAA receptor subunit genes. Many groups have found 
a correlation between AUDs and a synonymous SNP in exon 5 of the GABRA2 gene 
(rs279858 T to C; C allele associated with AUDs). However, the biological effects of this 
and other SNPs in this region are unknown. 
 Our lab has been using iPSC technology for the past few years to study AUDs. 
The lab has shown, using qPCR of mRNA, that a cluster of GABAA receptor subunit 
genes on chromosome 4p12 is expressed at minimal levels in neural cells derived from 
half of the iPSC lines (both controls and alcoholics) studied. Expression had a high 
correlation to genotype; lines with minimal expression tended to have at least one C 
allele of the rs279858 SNP. However, subunits for GABAA receptor subunit genes 
located on other chromosomes showed robust expression in all lines. Data from RNA-
seq of 12-week old iPSC-derived neural cultures showed similar results. 
 Results generated in this thesis project from chromatin immunoprecipitation 
experiments suggest that genetic factors linked to the rs279858 tag-SNP may moderate 
the developmental expression of the chromosome 4p12 GABAA receptor subunit gene 
cluster by altering epigenetic marks in the promoters of these genes. IPSCs from 
expresser lines had epigenetic marks typical of a bivalent promoter (both histone 
H3K4Me3 and H3K27Me3 marks present) for GABRA2. During neural development, the 
active H3K4Me3 modification remained with a reduction in levels of H3K27Me3 in 
neuroepithelial cells and differentiated neural cultures in expresser lines.  There were 
significantly lower levels of the H3K4Me3 mark in non-expresser iPSCs and neural cell 
cultures.  In addition, DNA methylation assays looking at a CpG island in the GABRA2 
promoter showed that fibroblasts of both expresser and non-expresser lines have very 
low CpG DNA methylation. However, after reprogramming, iPSCs from non-expresser 
lines show significant amounts of CpG island DNA methylation compared with iPSC 
lines which generate chromosome 4p12 GABAA receptor subunit gene expressing 
neural cells. 
 These data suggests that an AUD-linked functional genetic variation may have a 
direct influence on epigenetic state of the chromosome 4p12 GABAA receptor subunit 
gene cluster and that this effect, while appears very strong in generation of iPSCs, may 
have variable effects on epigenetic processes during specific times and brain regions 
during neural development. 
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Chapter 1. 
Introduction 
Alcohol Use Disorders 
 Alcohol use in the United States of America is common as more than 60% of US 
adults consume alcoholic beverages regularly. The National Institute of Alcohol Abuse 
and Alcoholism (NIAAA) defines moderate drinking as seven drinks per week and no 
more than three drinks in a day for women, and 14 drinks per week and no more than 
four drinks consumed in a day for men. This moderate alcohol consumption may have 
potential beneficial effects as studies have shown that these levels of alcohol use are 
associated with reduced the risk of heart disease and stroke (O'Keefe, Bybee et al. 
2007), type-2 diabetes (Conigrave, Hu et al. 2001, Djousse, Biggs et al. 2007), and 
gallstones (Leitzmann, Giovannucci et al. 1999). However, consuming alcohol in excess 
(drinking five or more drinks in a day more than five times in 30 days) can become 
hazardous to health and can cause an increase in blood pressure (Maheswaran, Gill et 
al. 1991, Husain, Ansari et al. 2014), liver disease (O'Shea, Dasarathy et al. 2010), and 
can also increase the risk for various cancers (Boffetta, Hashibe et al. 2006). In 
addition, excessive drinking increases the risk of developing an alcohol use disorder 
(AUD). The prevalence of AUDs in the US is estimated to be 13.9% (Grant, Goldstein et 
al. 2015), meaning approximately one in six adults who drink have some level of an 
AUD. This number is slightly higher in men (17.6% 12-month prevalence) than women 
(10.4% 12-month prevalence) (Grant, Goldstein et al. 2015). Diagnosis of AUDs is given 
according to the criteria in the Diagnostic Statistics Manual version 5 (DSM-5). To be 
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diagnosed with an AUD, the patient must meet two or more criteria provided within a 12-
month period. Briefly, the criteria include: consuming larger amounts of alcohol than 
intended, spending a great deal of time drinking, or recovering from drinking, craving 
alcohol (a new addition to the DSM-5), failing to fulfill obligations, a persistent desire to 
cut down on alcohol intake, giving up activities, continuing the use of alcohol despite 
interpersonal problems, acquired tolerance, and withdrawal symptoms. AUD severity 
ranges from mild (only meeting two criteria) to severe (meeting six or more criteria). In 
addition, AUDs are multifactorial and result from a combination of environmental factors 
and complex genetic factors complicating efforts to develop effective treatments even 
further. Comparison studies of monozygotic twins and dizygotic twins indicate that 
heritability rates of AUDs are 50-60% (Devor and Cloninger 1989, Prescott and Kendler 
1999, Goldman, Oroszi et al. 2005, Gelernter and Kranzler 2009). For initiation of use 
and early drinking it is thought that environmental effects outweigh genetic risks; an 
environment where alcohol is readily available may promote initiation of drinking, 
whereas an individual who is never exposed to alcohol will not initiate drinking. 
However, genetic effects play a greater role in the transition from moderate drinking to 
excessive drinking, alcohol dependence, and AUDs (Gelernter and Kranzler 2009). 
Because of the varying levels of severity of AUDs and the complex genetic and 
environmental factors, one size fits all treatments have shown limited relief in many 
alcoholic subjects (Litten, Egli et al. 2012). In order to develop more effective 
treatments, more complete understanding about the biology of AUDs is an important 
goal. Because there is a strong genetic component associated with AUDs, it seems a 
logical place to explore possible abnormalities and risk factors associated with AUDs. 
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The Genetics of AUDs 
 Genes directly involved with the metabolism of alcohol, including the genes 
coding for alcohol dehydrogenase, ADH1B, and aldehyde dehydrogenase, ALDH2, 
have been extensively studied in their role of AUD risk (Edenberg 2007). Mutations in 
these genes produce an accumulation of acetaldehyde, which results in the drinker 
feeling sick. Because of this effect, these mutations are considered to be protective 
against AUDs, as carriers of these mutations would generally avoid drinking alcohol and 
the associated adverse sensations generated by acetaldehyde. 
 In addition to these genes, genome-wide association studies (GWAS) looking at 
control subjects and alcoholic subjects have provided potential risk genes, including 
genes for subunits of GABAA receptors. However, the mechanism behind these variants 
is largely unknown. By elucidating the way in which these mutations act, we can provide 
more effective and personalized treatments. 
GABAA Receptors and AUDs 
 While the exact mechanism is unknown, acute alcohol exposure is known to 
potentiate GABAA receptor activity in the brain (Aguayo 1990). GABAA receptors are 
ligand-gated ion channels permeable to chloride and facilitate fast synaptic inhibition. 
GABA is the major inhibitory neurotransmitter in the brain and after binding to the 
GABAA receptor, induces the potentiation of the ion channel. These ion channels are 
pentamers generated by various compositions of 19 different GABAA subunits including 
α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-3. The genes encoding the most common subunits 
are located on five different chromosomes; chromosome 4p12 harbors γ1, α2, α4, and 
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β1; chromosome 5q34 (β2, α6, α1, γ2, and π); chromosome 15q12 (β3, α5, and γ3); 
chromosome Xq28 (ε, α3, and θ); and chromosome 1p36 (δ). The structure of the 
GABAA receptor and the layout of genes across human chromosomes is shown in 
Figure 1.1 (adapted from (Jacob, Moss et al. 2008)). Most commonly, the receptors are 
composed of two α subunits, two β subunits, and a γ subunit. However, the subunit 
composition for GABAA receptors varies by brain region and differences in subunit 
composition create unique electrophysiological and pharmacological properties 
(Barnard, Skolnick et al. 1998, Picton and Fisher 2007). The three most common 
combinations in the adult brain are α1β2γ2 (60%), α2β3γ2 (15%), and α3β3γ2 (10%) 
(Enoch 2008). During development, the subunit composition changes. In rats, primates, 
and humans, α1 subunit expression increases with development and α2 expression 
decreases showing an importance of the α2 subunit in early development (Laurie, 
Wisden et al. 1992, Hashimoto, Nguyen et al. 2009, Fillman, Duncan et al. 2010); a 
feature to remember in later discussion. 
 Numerous studies have shown associations of SNPs in a 140kb region spanning 
the 3’ end of GABRA2 and the intergenic region between GABRA2 and GABRG1 to 
AUDs (Covault, Gelernter et al. 2004, Edenberg, Dick et al. 2004, Lappalainen, 
Krupitsky et al. 2005, Fehr, Sander et al. 2006, Covault, Gelernter et al. 2008, Enoch, 
Hodgkinson et al. 2009, Olfson and Bierut 2012). Haplomaps of this area show high 
correlations of SNPs within the 140kb haplotype block to expression status of 
chromosome 4 GABAA receptor subunit genes in iPSC-derived neural cell culture 
versus SNPs outside the haplotype block, which are not associated (Figure 1.2). The 
most reproducible studies (see above) have reported an association of AUDs with a  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p=0.34 
rs2351439
p=0.77 
rs10028945
p=0.33 
rs7660336
α2
140kb haplotype block
Figure 1.2. Diagram of the GABAA receptor subunit gene cluster on chromosome 4p12. The image 
shooting out of the chromosome is the 140kb haplotype block diagram generated by Hapmap. The 
SNPs with p-values are relative to the association of genotype to iPSC-derived neural cell culture 
chromosome 4 GABAA receptor subunit gene expression phenotype. P-values within the box have 
strong associations within this region and those outside of the box do not have strong associations.
AUD associated region
*p=0.007 
rs279858 
rs529826 
rs534459
*p=0.006 
rs573400 
rs567926 
rs1440133
synonymous tag-SNP for this region, rs279858, which is located in exon 5 of the 
GABRA2 gene and involves a T to C variation; the C-allele being associated with AUD 
risk. It has been shown that this AUD risk C-allele has a frequency of 40% in controls 
and 46% in alcoholics (Covault, Gelernter et al. 2008). GABRA2 is widespread in early 
development and becomes more focalized in adult mice showing the highest expression 
in the hippocampus and limbic regions (Pirker, Schwarzer et al. 2000). The GABRA2 
alcohol risk allele is also associated with intermediate neural phenotypes such as fast 
beta-frequency EEG activity (Edenberg, Dick et al. 2004), activation of the insular cortex 
during reward anticipation (Villafuerte, Trucco et al. 2014), changes in activation of the 
medial frontal cortex by alcohol cues (Kareken, Liang et al. 2010), and increased 
activation of the nucleus accumbens in reward anticipation (Heitzeg, Villafuerte et al. 
2014). GABAA receptors containing the α2 subunit mediate the anxiolytic effects of 
benzodiazepines, which are used to lessen withdrawal symptoms in alcoholics. 
However, the more proximal molecular effects associated with the SNPs in this 
haplotype block have yet to be elucidated. 
  
A New Model to Study AUDs 
 The study of GABAA receptor subunit genes in mice has been highly informative 
for the study of human diseases and disorders, including AUDs. The GABAA receptor 
subunit genes in mice located on chromosomes 5, 11, 7, X, and 4 are orthologous to the 
placement on human chromosomes 4p12, 5q34, 15q12, Xq28, and 1p36, respectively 
(Uusi-Oukari, Heikkila et al. 2000). However, while there are many similarities present, a 
very important component of AUD risk is SNPs that are specific to the human genome. 
 7
Mouse models have a great ability to show us what happens when full genes are 
knocked out, or knocked in, and what the consequences are, but human disease-
associated genetics are more nuanced than this. So while rodent research has brought 
the field a long way in terms of researching basic biological genetics related to AUD risk, 
the next leg of research must be catered to the human condition. 
 One way to study disease associated genetic variants in human tissue is through 
iPSC technology. Since 2007 when Takahashi and Yamanaka et al. showed the 
reprogramming of human fibroblasts into induced pluripotent stem cells, the use of this 
technology has blossomed (Takahashi, Tanabe et al. 2007). Reprogramming is 
achieved by introducing four factors (Oct3/4, Sox2, Klf4, and c-Myc) into fibroblasts to 
reset cells back to a pluripotent state. One of the greatest difficulties when researching 
human neurological disorders and diseases is obtaining viable tissue with which to 
perform research. The options were either to mimic the illness in an animal model, or 
obtain post-mortem brain tissue. With animal models there is hope the findings are 
translatable to humans. However, the ability to translate findings from these approaches 
has limitations. It’s been shown that less than 8% of cancer clinical trials have translated 
from mice to humans (Mak, Evaniew et al. 2014). One example of these trials that 
showed promise in mice, but failed in humans, is the TGN1412 trial. In this trial, all of 
the six healthy volunteers who received the TGN1412 monoclonal antibody, which was 
supposed to activate T-cells without toxic effects, had multi-organ failure and were 
admitted to the hospital (Suntharalingam, Perry et al. 2006). Additionally, all treatments 
for amyotrophic lateral sclerosis (ALS) in the last ten years that showed effective results 
in mouse models (primarily TDP43 and SOD1 mutants) have failed (or been minimally 
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effective) in human trials (Perrin 2014). In terms of post-mortem brain tissue, obtaining 
these samples from relevant subjects at early as well as late stages of disease is not 
always easy, and when the tissue is obtained the quality and integrity of the cells is 
often severely compromised. In addition, post-mortem brain tissue typically only gives a 
look at the outcome of the illness at later stages after years of variable treatments and 
possible co-morbidities, which is also subject to limitations. IPSC technology has 
allowed studies of a number of neurological illnesses at a cellular and molecular level 
never before achievable. Studies done with iPSCs and iPSC-derived neurons have 
provided insights and advancements in the research of many neurological illnesses 
including schizophrenia (Brennand, Simone et al. 2011), bipolar disorder (O'Shea and 
McInnis 2015), ALS (Cashman and Lazzerini Ospri 2013, Chen, Qian et al. 2014), and 
Prader-Willi and Angelman syndromes (Chamberlain, Chen et al. 2010, Cruvinel, 
Budinetz et al. 2014). The use of iPSCs to create live neurons from multiple subjects 
carrying defined gene variants, while maintaining the genetic makeup of the subjects, 
allows us to choose subjects with and without disease associated variants and study the 
possible differences in the neurons associated with these specific human genetic 
variants. 
 Research done in the lab using iPSC-derived forebrain neural cultures has 
provided us with some interesting questions regarding the use of iPSCs to study AUDs. 
A gene expression analysis using quantitative PCR (qPCR) was done to examine genes 
previously associated with AUDs (genes encoding GABAA receptor subunits and NMDA 
receptor subunits) in control subjects and alcoholic subjects with different genotypes of 
the rs279858 SNP in GABRA2; two T alleles (TT), one T allele and one C allele (TC), or 
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two C alleles (CC). When looking at the GABAA receptor genes, it was discovered that 
gene expression of a cluster of genes encoding GABAA subunits located on 
chromosome 4p12 (GABRG1, GABRA2, GABRA4, GABRB1) was very low in 
approximately half of the lines examined. Ten of 11 lines with the TT genotype 
expressed this gene cluster (both control and alcoholic subjects), while only four of 14 
CC lines expressed the gene cluster, and five of 11 CT lines has the expresser 
phenotype. Cluster analysis separated the lines into two groups: lines which express the 
GABAA receptor subunit gene cluster on chromosome 4p12, or “expressers,” and lines 
which show reduced or minimal expression of the GABAA receptor subunit gene cluster, 
or “non-expressers” (Lieberman, Kranzler et al. 2015). 
 In addition to qPCR data, RNA-seq data was also available for a subset of 
samples providing genome wide gene expression data. RNAseq data was used to 
calculate correlations between GABAA receptor subunit genes on chromosome 4p12 
and other GABAA receptor subunit genes located on other chromosomes. Genes on 
chromosome 4p12 were found to be highly correlated, whereas genes on other 
chromosomes showed little correlation to GABRA2 (chromosome 4p12). Utilizing this 
RNA-seq data, we generated a graph showing the average values of the reads per 
kilobase of transcript per million reads mapped (RPKM) for GABAA subunits on 
chromosomes 1, 4, 5, 15, and X. In Figure 1.3A, there is a clear difference between the 
expresser lines and the non-expresser lines in the gene cluster on chromosome 4p12, 
as expected and the non-expresser lines have virtually no expression of these genes. 
Figure 1.3B shows that for GABAA subunit genes on other chromosomes there is little 
change in expression among expresser lines and non-expresser lines. While these  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Figure 1.3. Graphical representation of RPKM values from RNA-seq data in Lieberman et al., 
2015. (A) Expression of GABAA receptor subunit genes located on chromosome 4p12 in 
expressers and non-expressers. Expressers show significantly greater RPKM values than the non-
expressers. (B) Expression of GABAA receptor subunit genes located on chromosomes 5, 15, and 
X. Expression does not differ between expressers and non-expressers.
chromosome 4p12 GABAA receptor subunit genes have low RPKM values in these 
cultures (low RPKM values can be unreliable (Mortazavi, Williams et al. 2008)), the 
qPCR data in Lieberman et al., 2015 verify the findings from the RNA-seq data and 
suggest that what we are seeing is a reproducible phenotype present in ~40% of lines. 
Additionally, Lieberman et al., 2015 looked at results from post-mortem tissue 
databases and saw no genotype related changes in GABRA2 expression in any of the 
samples indicating this could potentially be a developmental phenotype. 
 Data from the RNA-seq studies in Lieberman et al., 2015, show that the genes 
flanking the chromosome 4p12 GABAA receptor subunit gene cluster are expressed 
similarly in both expresser and non-expresser lines. Since this phenotype is confined to 
the chromosome 4p12 GABAA receptor subunit gene cluster, we have reason to believe 
that there is a common regulatory element for this ~1.4mb gene cluster. There is 
evidence that this may be a common pattern for clustered GABAA receptor subunit 
genes. As mentioned above, the distribution of GABAA receptor subunit genes on the 
chromosomes of mice is orthologous to that of humans. In mice it has be demonstrated 
that long distance regulation of multiple GABAA receptor subunit genes on chromosome 
11 (chromosome 5 in humans) exist. A study done by Uusi-Oukari et al., 2000, found 
that α6 -/- mice showed decreased mRNA expression of the β2 and α1 subunits 
suggesting a common regulatory element that acts over long distances (Uusi-Oukari, 
Heikkila et al. 2000). This finding in mice, together with the orthologous layout of the 
GABAA receptor subunit genes on chromosomes, led us to believe we are seeing a 
similar mechanism in the human GABAA receptor subunit gene cluster on chromosome 
4p12. 
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 The question remains, what is going on that has linked the genotype of a 
synonymous tag-SNP to expression levels of the GABAA receptor subunit genes 
clustered on chromosome 4p12 in iPSC-derived neurons? One potential modulator of 
this cluster could be a change in epigenetic modifications. 
Epigenetic modifications and gene expression 
 Epigenetics involves mitotically heritable modifications beyond the genomic DNA 
sequence. In recent years, the field has been expanding rapidly. What was once 
focused on primarily X-linked phenotypes and imprinted genes is now opening into a 
world where expression of autosomal genes is found to be heavily influenced by 
developmental and environmental, non-genetic features via epigenetic regulation. 
 In order for DNA to be more compact yet efficiently accessed, it is wrapped 
around histone octamers made up of two H2A, two H2B, two H3, and two H4 histone 
subunits. Approximately 146bp of double stranded DNA is wrapped around a histone 
octamer creating what is called a nucleosome. Each nucleosome is connected by linker 
DNA bound to an H1 subunit. The histone subunits each have an N-terminal tail that 
can be modified by a number of post-translational modifications including methylation, 
acetylation, ubiquitylation, and phosphorylation (Cedar and Bergman 2009). The histone 
subunit affected, the location of the residue modified on the tail of the histone subunit, 
the type of modification, and the degree of modification can all alter the 3D chromatin 
structure and influence the availability of DNA for transcription. For example, the lysine 
at position 4 (K4) on the tail of the histone 3 subunit (H3) can be tri-methylated 
(H3K4me3) and this mark is seen in up to ~75% of gene promoters and is associated 
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with active gene expression (Gu and Lee 2013). Another common histone modification 
is the tri-methylation (me3) of lysine 27 (K27) on the histone 3 subunit (H3K27me3). 
This mark is associated with repression of transcription. Examples of other lysine 
modifications on the histone 3 subunit tail include H3K9me3, a repressive mark found in 
differentiated cells, and H3K36me3, a mark found in actively transcribed genes (Zhou, 
Goren et al. 2011). 
 Methylation of histone lysine residues is catalyzed by a number of different 
histone methyltransferases (HMTs) also known as “methyl writers” (Ruthenburg, Allis et 
al. 2007). H3K4, for example, is methylated by at least 14 known HMTs, all of which 
contain a SET (a protein domain characterized in Drosophila: Su(var)3-9, Enhancer of 
zeste, Trithorax (Cheng, Collins et al. 2005)) domain. They include: SET1A, SET1B, 
SET7/9, MLL1-5, SETMAR, ASH1L, PRDM9, and SMYD1-3 (Gu and Lee 2013). The 
SET domains are either related to yeast Set1 and Drosophila Trx as with MLL1-5, 
SET1A, and SET1B, or unrelated as with SET7/9, SETMAR, ASH1L, PRDM9, and 
SMYD1-3 (Ruthenburg, Allis et al. 2007, Gu and Lee 2013). The SET domain in these 
proteins catalyzes the transfer of the methyl group of S-adenosylmethionine to H3K4 
(Gu and Lee 2013). In the case of H3K27 methylation, EZH2, which is part of the 
polycomb repressive complex 2 (PRC2), initiates methylation (Cedar and Bergman 
2009). 
 Similar to methylation, demethylation of histone lysine residues is not only 
dependent on the position of the lysine, but is also sometimes methylation state 
specific. For example, Jumonji C (JmjC) domain proteins UTX and JMJD3 are specific 
demethylases for di-methylated H3K27 and tri-methylated H3K27 residues, with 
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preference for the latter (Swigut and Wysocka 2007). Demethylation of di- and tri-
methylated H3K4 is initiated by KDM5A-D (Gu and Lee 2013). 
 Evaluation of histone modification profiles for specific loci is done using 
chromatin immunoprecipitation (ChIP) assays, which examines the interaction of 
proteins with DNA. For example, ChIP can test to see if a transcription factor interacts 
with a promoter of interest, or whether a particular histone modification is enriched in a 
given location on the genome. The ChIP process (depicted in Figure 1.4) involves the 
cross-linking of histone proteins to DNA with formaldehyde followed by controlled 
sonication. The chromatin is then split equally into separate reactions; one for input 
(unimmunoprecipitated DNA) and the remaining into different immunoprecipitations with 
antibodies to histone proteins of interest (i.e. H3K4me3 or H3K27me3). All samples are 
then reverse cross-linked and treated with RNase A and proteinase K, and then the 
DNA is purified. The purified DNA from the input sample and IPs are then analyzed via 
sequencing or quantitative PCR (qPCR). 
 Initial research done by Ernst and Kellis in 2010 found 51 annotated chromatin 
states in human T-cells using a Hidden Markov Model (Ernst and Kellis 2010). The 
following year, Ernst et al. (2011) looked at nine different chromatin marks in nine 
different cell types to create regulatory predictions and they defined 15 broad 
annotations of chromatin states. The frequency of each chromatin mark was analyzed 
and charted to show which annotations best fit each chromatin mark. For example, 
H3K4me3 was found to be associated with strong promoters with 99% frequency. 
CTCF, a CCCTC-binding protein, was annotated as an insulator with 92% frequency, 
and H3K27me3 was associated and annotated as an inactive/poised promoter with 72%  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frequency (Ernst, Kheradpour et al. 2011). An example of the data from Ernst et al. 
2011, is represented in the pink bar at the top of Figure 1.5. This shows that this region 
was found to be in a bivalent/poised state in embryonic stem (ES) cells. Additionally, 
other archived ChIP-sequencing data on the UCSC Genome Browser (http://
genome.ucsc.edu/) also shows a bivalent/poised promoter for GABRA2 in H1 and H9 
ES cells and iPSCs (iPS6.9) (Figure 1.5). A poised promoter has both the active, 
H3K4me3, and repressive, H3K27me3, marks present. In the pluripotent state, the gene 
is inactive, but poised for expression once its fate has been determined. For example, 
differentiated neurons maintain the active mark, and the the enrichment of the 
repressive mark decreases in this cell type. The bottom two tracks on Figure 1.5 show 
profiles for the active mark and repressive mark in post-mortem mid-frontal lobe brain 
tissue in which the bivalent state modifications have resolved (H3K4me3 is relatively 
more absent than the H3K27me3); consistent with GABRA2 expression in the brain, the 
poised promoter was “switched” to an active promoter. 
DNA methylation and CpG islands 
 Another feature of epigenetic regulation is DNA methylation. While most CpG 
sites throughout the genome are methylated, there are regions (typically ~1kb in length) 
in the genome with a higher than average GC content, known as CpG islands (Jones 
2012), which are typically unmethylated and are found at the promoter of many genes 
(Moore, Le et al. 2013). While uncommon, DNA methylation at CpG islands does occur 
and is associated with transcriptional silencing and is important in gene regulation and 
development (Rose and Klose 2014). In addition, aberrant DNA methylation of cancer  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suppresser genes results in a variety of cancers (Cedar and Bergman 2009). 
 DNA methylation occurs when a methyl group is added to the cytosine ring at 
CpG dinucleotides. This process is mediated by a family of DNA methyltransferases 
(DNMTs) (Moore, Le et al. 2013). DNMT1 is necessary for the maintenance of DNA 
methylation. During DNA replication, DNMT1 methylates the daughter strands in 
reference to the parental methylation patterns (Esteller 2007). DNMT1 is crucial for 
development, and studies have shown that the knockout of DNMT1 in mice is 
embryonically lethal (Li, Bestor et al. 1992). De novo methylation is mediated by 
DNMT3A and DNMT3B. While knockout of DNMT3B in mice is embryonically lethal, 
DNMT3A  knockout mice survive, but typically not more than 4 weeks, (Okano, Bell et 
al. 1999).  
 It is known that there is some opposition between DNA methylation and the 
presence of H3K4 methylated histones. DNMT3L, a catalytically inactive DNMT, binds 
nucleosomes at the H3 N-terminus and can initiate de novo DNA methylation with the 
aid of DNMT3A2 and DNMT3B. However, when H3 is methylated (mono-, di-, tri-) at 
lysine 4 (K4), DNMT3L can no longer bind and DNA methylation is inhibited (Ooi, Qiu et 
al. 2007). 
 DNA methylation is ‘read’ by a number of proteins belonging to three separate 
families. Methyl-CpG-binding domain (MBD) proteins and zinc-finger domain proteins 
generally bind methylated DNA and recruit repressor complexes leading to 
transcriptional repression. UHRF (ubiquitin-like containing PHD and RING finger 
domain) proteins are important for DNA methylation maintenance as they bind DNMT1, 
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which (as mentioned above) aids in DNA methylation maintenance on daughter strands 
during replication (Moore, Le et al. 2013). 
Thesis Objectives 
Hypothesis 
 Our hypothesis is that a yet-to-be-identified functional SNP represented by the 
tag-SNP rs279858 in the 140kb GABRA2 haplotype block is influencing the 1.5mb 
chromosome 4p12 GABAA receptor subunit gene cluster through epigenetic 
mechanisms including changes in histone modifications and DNA methylation. 
Specifically, we hypothesize that the non-expresser neurons are retaining repressive 
(H3K27me3) epigenetic marks and/or are losing the activating (H3K4me3) mark during 
development. In addition, we hypothesize that the absence of the H3K4me3 
modification in these lines allows for DNA methylation of the CpG island located in the 
promoters of the GABAA receptor subunit gene cluster on chromosome 4p12. 
Alternatively, DNA methylation is inhibiting the ability of histone methyltransferases to 
methylate H3K4 in this region. 
Aims 
 1. Compare the histone modification profiles for an active mark, H3K4me3, and a 
repressive mark, H3K27me3, in the promoters of the GABAA receptor subunit genes in 
iPSC-derived neural cultures that express the chromosome 4p12 gene cluster 
(expresser lines) as well as those with reduced expression (non-expressers). 
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 2. Characterize whether a bivalent “poised” promoter type histone modification 
profile is present in iPSCs and whether this differs by neural chromosome 4p12 GABAA 
receptor subunit gene cluster expression phenotype. 
 3. Evaluate and compare DNA methylation profiles at a site in the CpG island in 
the promoter of GABRA2, as well as neighboring genes in expresser and non-expresser 
iPSC lines. 
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Chapter 2. 
Histone Modification Profiles in iPSCs and iPSC-derived cells 
Background 
 The process of reprogramming fibroblasts into iPSCs changes epigenetic 
features, including histone modifications, chromatin structure, and DNA availability 
(Liang and Zhang 2013). To evaluate the potential for epigenetic regulation via changes 
in histone methylation on the chromosome 4p12 GABAA receptor subunit gene cluster, 
ChIP-seq and ChIP-qPCR were conducted. We used an antibody specific for the 
H3K4me3 modification, which is associated with the promoters of active genes, and an 
antibody specific for the H3K27me3 modification, which is associated with poised 
promoters in pluripotent cells and with facultative heterochromatin and repressed genes 
in differentiated cells (Ernst, Kheradpour et al. 2011). Using the UCSC Genome 
Broswer, we evaluated archived raw ChIP-seq data tracks for H3K4me3 and 
H3K27me3 in ES cells and iPSCs. These tracks, shown in Figure 1.5, were used to 
indicate the location of enrichment of our two marks of interest. In pluripotent stem cells, 
archived ChIP-seq data indicates the GABRA2 promoter is bivalent, or “poised,” 
showing enrichment of both H3K4me3 and H3K27me3 marks, readying the gene to 
either be expressed, or repressed during differentiation depending on cell type and 
location provided by chemical and developmental cues. In contrast, ChIP-seq tracks 
from post-mortem brain mid frontal lobe (BMFL) tissue show decreased H3K27me3 
enrichment, and maintenance of the active H3K4me3 mark. Our hypothesis was that 
non-expresser lines retain the H3K27me3 repressive enrichment and lose enrichment of 
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H3K4me3, the active mark. To assess this, we used ChIP with H3K4me3 followed by 
genome wide sequencing to assess and global changes that may be affecting the 
cluster of GABAA receptor subunit genes on chromosome 4p12 and ChIP followed by 
quantitative PCR (qPCR) to target specific genes/promoters of interest. 
Methods 
Cell lines 
 Lines were the same as used in the 2015 Lieberman study (Lieberman, Kranzler 
et al. 2015). Briefly, skin punch biopsies were taken from 21 patients and were cultured 
as fibroblasts. Fibroblasts were reprogrammed into induced pluripotent stem cells 
(iPSCs) by the Stem Cell Core at the University of Connecticut Health Center. 
IPSC differentiation into forebrain neurons 
 Neuronal differentiation was done using the method described in Zeng et al. 
(Zeng, Guo et al. 2010). Briefly, iPSCs were cultured on a feeder layer of irradiated 
mouse embryonic fibroblasts with human Embryonic Stem Cell Media (hESM) 
comprised of DMEM/F12, ß-ME, L-glutamine, Knockout SR, MEM NEAA, and bFGF to 
reduce differentiation of colonies. To passage the cells, colonies were treated with 1mg/
ml dispase (in DMEM/F12) for five minutes to loosen attachment to the plate and feeder 
cells. Dispase was removed and colonies were washed one time with DMEM/F12. 
HESM was added and plates were scraped with a 5ml pipette to break up and release 
colonies. A small portion of the colony pieces was passaged to another plate of 
irradiated mouse embryonic fibroblasts (iMEFs), and for neuronal differentiation, the 
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remaining broken up colonies were transferred to a T-75 suspension flask containing 
ESM without bFGF. Stage 1: Medium was changed every day for six days by letting the 
cell clusters, also known as embryoid bodies (EBs), settle to the bottom before 
removing old medium. Stage 2: On day seven, EBs were spun down at 1,000 rpm for 
five minutes and transferred to a new T-75 flask with Neuronal Induction Media (NIM) 
containing DMEM/F12, heparin, MEM NEAA, and N2 supplement. EBs were cultured in 
NIM for three to four days changing media every other day. Stage 3: EBs were then 
plated onto tissue culture treated plates with NIM containing 10% FBS to aid in EB 
attachment. Twelve to 14 hours after plating, medium was changed to NIM without FBS, 
and then every other day for 10-14 days. Stage 4: Neuroepithelial cell colonies from 
plates were dislodged from the plates with a stream of medium from a 1ml pipette and 
the detached clusters were transferred to a T-75 suspension flask to culture as 
neurospheres. These neurospheres were cultured for seven days in NIM with B27. 
Stage 5: Neurospheres greater than 300µm were separated from the other clusters and 
dissociated by incubating cells with Accutase for five minutes at 37˚C, spun down, and 
then rinsed with Neurobasal medium. Neurospheres were plated on 12-well plates 
coated with 20ng/ml laminin. Neurons were cultured in Neuronal Differentiation Medium 
(NDM) containing BDNF, GDNF, IGF, laminin, L-glucose, B27, and N2. Medium was 
changed every three to four days for 12 weeks, during which time they become 
differentiated  neurons expressing GABA and glutamate receptor genes. IPSC lines and 
iPSC-derived neural cultures from these lines have been previously characterized in our 
lab (see Lieberman et al., 2015). 
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Chromatin immunoprecipitation (ChIP) 
 For neurons, ChIP was done using the Millipore EZ-Magna ChIP (17-409) 
protocol. For iPSCs and neuroepithelial cells, a combination of multiple protocols was 
used including the Millipore EZ-Magna ChIP protocol, a high-throughput ChIP protocol 
(Blecher-Gonen, Barnett-Itzhaki et al. 2013), and the Cotney et al. protocol (Cotney and 
Noonan 2015). IPSCs from a 10cm petri dish, or neurons from 6-12 24-well wells, were 
fixed with a final concentrations of 1% formaldehyde (freshly made) to crosslink 
histones to DNA and 1X glycine was then added to quench the excess formaldehyde. 
Cells were washed twice with 1X PBS and then a third time with 1X PBS with Protease 
Inhibitor Cocktail II (Millipore). Cells were either processed immediately or frozen at 
-80˚C until further use. Cells were pelleted at 1,000 rpm for five minutes. Cell pellets 
were suspended in 1ml of cell lysis buffer containing 50mM Tris-HCl (pH 8.0), 140mM 
NaCl, 1mM EDTA, 10% glycerol, 0.5% NP-40, and 0.25% Triton X-100. Samples were 
incubated on ice for 20 minutes. Cells were disrupted using a 2ml Dounc homogenizer 
with pestle B (Kontes) for 30 strokes. Lysates were spun down at 2,000g for 5 minutes 
at 4˚C and supernatant was discarded. Pellets were resuspended in 300µl nuclear lysis 
buffer containing 10mM Tris-HCl (pH 8.0), 1mM EDTA, 0.5mM EGTA, and 0.2% SDS 
and incubated on ice for 20 minutes. Chromatin was then sheared into 200-800bp 
fragments using controlled sonication with a QSonica sonicator for 30 minutes in 10 
second bursts. To evaluate sonication efficiency, 5µl of sonicated material was treated 
with RNase A for 30 minutes at 37˚C, followed by a proteinase K treatment at 37˚C and 
then reversed crosslinks at 65˚C. The DNA was then run on an agarose gel. The DNA 
was a smear localized to 200-800bp. Sonicated material was spun down to remove 
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debris and kept at -80˚C until further analysis. Frozen pellets were thawed on ice, and 
sheared chromatin was then immunoprecipitated with ChIP-validated antibodies from 
Millipore against the active mark, histone 3 tri-methylated lysine 4 (H3K4me3; Millipore, 
17-614), and against the repressive mark, histone 3 tri-methylated lysine 27 
(H3K27me3; Millipore, 17-622). Antibodies were tested for binding specificity using the 
Millipore AbSurance Histone H3 Antibody Specificity Array (Millipore, 16-667). 
Antibodies were coupled to washed protein-G magnetic beads (Millipore, 16-662) in 
blocking binding buffer containing 1% BSA and 1% Tween-20 in PBS in low-bind 1.5ml 
tubes and incubated at room temperature for one hour. Beads were then separated 
from the buffer using a magnetic rack. The supernatant was discarded and the beads 
were resuspended in a portion of sonicated material diluted to 500µl with dilution buffer 
consisting of 0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris-HCl, 167mM 
NaCl, and protease inhibitor cocktail II (Millipore, 539132). Samples were incubated 
overnight at 4˚C on a rotator. The following day, beads were separated using the 
magnetic rack and the supernatant was discarded. The beads were resuspended in 
180µl dilution buffer with protease inhibitors and transferred to a well in a pre-chilled 96-
well PCR plate. Beads were separated using a magnetic rack for 96-well plates and the 
supernatant was discarded. Beads were washed with 180µl cold Low Salt Immune 
Complex Wash Buffer (Millipore, 20-154) twice, 180µl High Salt Immune Complex Wash 
Buffer (Millipore, 20-155) twice, LiCl Immune Complex Wash Buffer (Millipore, 20-156) 
twice, and TE buffer (Millipore, 20-157). Beads were washed by moving the plate from 
side to side on the magnetic rack. After the removal of the TE buffer, beads were 
resuspended in 50µl elution buffer consisting of 10 mM Tris-HCl (pH 8.0), 5 mM EDTA 
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(pH 8.0), 300 mM NaCl, and 0.5% SDS. Samples were treated with 1µg RNase A for 30 
minutes at 37˚C and then proteinase K treated for 2 hours at 37˚C followed by a 65˚C 
incubation overnight. The following day, beads were separated using the magnetic rack 
and the supernatant was moved to a new plate. To purify the DNA, Agencourt AMPure 
XP beads (Beckman Coulter, A63881) were added at 2.3x the volume of supernatant 
and mixed by pipetting up and down 25 times. Samples were incubated at room 
temperature for 2 minutes and then the beads were allowed to be separated using the 
magnetic rack for 4 minutes. Supernatant was removed and beads were washed twice 
with 100µl 70% EtOH for 30 seconds while the plate remained on the rack. After all of 
the ethanol was removed the plate was removed from the rack. The beads were dried at 
room temperature for 4 minutes. Beads were then resuspended in 60µl 10mM Tris-HCl 
(pH 8.0) and mixed by pipetting up and down 25x. Samples were incubated at room 
temperature for 2 minutes. The plate was returned to the rack for 4 minutes to separate 
out the beads and the supernatant was transferred to another plate. 
 The concentration of ChIP DNA was measured using the Qubit dsDNA High 
Sensitivity Assay Kit (Thermo Fisher Scientific, Q32851). ChIP DNA was then used to 
construct sequencing libraries (undiluted), or diluted to 50pg/µl for qPCR. 
ChIP-seq 
 ChIP was done with both iPSCs and iPSC-derived neuroepithelial cells from both 
an expresser line, 563-9, and a non-expresser line, 559-5, and immunoprecipitated with 
H3K4me3. Resulting ChIP-DNA from the immunoprecipitations, as well as inputs for 
each cell type (563-9 iPSC, 563-9 neuroepithelial cells, 559-5 iPSCs, and 559-5 
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neuroepithelial cells), was then processed using the Illumina TruSeq ChIP Sample 
Preparation protocol. Briefly, End Repair was done on 50µl of 100-200pg/µl ChIP or 
input DNA to blunt the ends by removing 3’ overhangs and filling in 5’ overhangs. Next 
the 3’ ends were adenylated to prevent fragments from ligating to one another in the 
next step where multiple indexing adaptors are ligated to the DNA fragments for 
hybridization. The ligation products were run on an agarose gel, the region of the gel 
containing DNA in the 200-350bp size-range was excised, and DNA was extracted 
using a gel extraction kit (Qiagen, 28704). DNA was examined using a TapeStation 
instrument (Agilent) to confirm DNA fragments were in the 250-300bp size-range, which 
is optimal for efficient cluster generation. The purified adapter modified DNA  products 
were amplified using PCR. The ChIP DNA target size range was validated again using 
the TapeStation and the library DNA was quantified using the NEBNext Quant Kit for 
Illumina  (New England Biolabs, E7630S). The DNA library samples were normalized 
and pooled for sequencing using the Illumina NextSeq 500 system with a High Output 
Kit (75 cycles; Illumina, FC-404-1005). 
 ChIP-seq data was analyzed first by SICKLE for adaptive trimming of the reads 
to remove poor quality ends. Reads were aligned to the genome (hg19) using STAR. 
HOMER was then used to create bedGraph files to import into the UCSC Genome 
Browser to view raw data pile-up tracks, find peak calls, annotate peaks, and create a 
meta-gene for each line. DiffBind was used to contrast peaks between samples with 
ChIP-seq data.  
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Quantitative real-time PCR for ChIP 
 To obtain multiple primers specific for the GABAA receptor subunit genes’ 
promoter regions, the target genome sequence 1000 bases upstream of each gene 
(guided from archived ChIP-seq data from the UCSC genome browser) was entered 
into PCR Tiler (http://pcrtiler.alaingervais.org:8080/PCRTiler/), which calculates primer 
pairs with specified annealing temperatures, GC content, and product specificity. 
Primers were designed for the GABRA2 (gene of interest; chromosome 4) promoter, 
GABRB2 (chromosome 5) promoter as a comparative control, GUF1 (a gene flanking 
the chromosome 4 cluster) as another comparative control, a region negative for both 
H3K4me3 and H3K27me3 enrichment near GABRA2 (negative control), and MYOD1 (a 
positive control for H3K27me3 enrichment). A positive control for H3K4me3 enrichment 
were the control primers for GAPDH, supplied with the ChIP antibody. For primer 
sequences, see Table 2.1. QPCR was done in duplicate using 20µl reactions with 1µl 
50pg ChIP DNA, primers, and SYBR Green Master Mix (Thermo Fisher Scientific, 
4309155). QPCR was conducted using an ABI 7500 PCR System. The protocol was 
95˚C for 10 minutes, and 40 cycles of 95˚C for 15 seconds and 60˚C for 1 minute. To 
calculate fold over input, the average Ct values of duplicates were calculated and then 
entered into the equation: 2(Input Ct average – IP Ct average). Fold enrichments were compared 
between groups using a 2-tailed student’s t-test. 
Results 
 To assess possible differences in histone modification enrichment between 
expresser and non-expresser lines, we examined 12- to 15-week (post plating) neural  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Primer Target Sequence (5'-3') Tm (˚C)
ChpGA2_C Forward
GABRA2
CTC CCA AGT TTC CTA TCT CGT CAA 56.2
ChpGA2_C Reverse AGT GTC TCT ATC GGG ACC AAC G 58.2
GAPDH Forward
GAPDH
TAC TAG CGG TTT TAC GGG CG 57.2
GAPDH Reverse TCG AAC AGG AGG AGC AGA GAG CGA 63.3
MYOD1 Forward
MYOD1
CGC CAG GAT ATG GAG CTA CT 56.2
MYOD1 Reverse CGG GTC GTC ATA GAA GTC GT 56.3
ChpGB2_B Forward
GABRB2
CTC TGG GTG TGC GAG TCC 58.1
ChpGB2_B Reverse CGG AGC GGT CCC TAG AAG 57.3
GUF1 Forward
GUF1
GGC TAC CGA CAG GCT CTA 56.1
GUF1 Reverse GCC CTA TAC ATG TCC AAG ATC G 55
Negative control Forward Unenriched 
region in 
GABRA2
TGA GGC TAG AGG GTA TAA AGT G 53.3
Negative control Reverse ACT GGT AAC CAA CTT CAA ACA A 52.7
Tabel 2.1. Primer sequences and melting temperatures for ChIP-qPCR.
cultures of previously identified lines from Lieberman et al. 2015. Using archived ChIP-
seq data tracks from the Genome Browser, we targeted the sequence of the promoter 
region of GABRA2 using PCR tiler to obtain primers that coincided with the H3K4me3 
and H3K27me3 peaks. Histone modification enrichment was analyzed by ChIP-qPCR 
using antibodies to H3K4me3 and H3K27me3, and data was measured as a percent of 
the input DNA. We found that the active mark, H3K4me3, was robustly enriched at the 
GABRA2 promoter in expresser neural cultures (n=7), but not in non-expresser lines 
(n=4) (Figure 2.1A, *p=0.02). The repressive mark, H3K27me3, showed no significant 
difference between expresser (n=6) and non-expresser (n=2) neurons  (Figure 2.1B, 
p=0.7). GAPDH, a housekeeping gene, was used as a positive control for H3K4me3 
enrichment and showed no significant difference between expresser (n=7) and non-
expresser (n=4) lines (Figure 2.1C, p=0.1). The GAPDH promoter, which is a strong 
promoter, had no enrichment of H3K27me3 in either expressers (n=6) or non-
expressers (n=2) as expected (Figure 2.1D, p=0.25). This suggested a link between 
expression status and H3K4me3 enrichment in neurons. 
ChIP-seq to evaluate genome wide enrichment of H3K4me3 
 Messenger RNA (mRNA) expression timelines were previously done in the lab 
looking at GABRA1 and GABRG2, located on chromosome 5, and GABRA2 and 
GABRG1, located on chromosome 4p12. Expression data from two TT lines 
(expressers) and two CC lines (non-expressers) from iPSCs, neuroepithelial cells (NE), 
and neural cell cultures 2-, 6-, and 15-weeks (post-plating). mRNA expression data for 
genes located on chromosome 5, GABRA1 and GABRG2, show no expression in  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Figure 2.1. ChIP-qPCR data for expresser and non-expresser 12-15 week iPSC-derived neurons. (A) 
H3K4me3 enrichment at the GABRA2 promoter (expressers n=7 and non-expressers n=4; *p=0.02). 
(B) H3K27me3 enrichment at the GABRA2 promoter (expressers n=6 and non-expressers n=2; 
p=0.74). (C) H3K4me3 enrichment at the GAPDH promoter (expressers n=7 and non-expressers n=4; 
p=0.1). (D) H3K27me3 enrichment at the GAPDH promoter (expressers n=7 and non-expressers n=4; 
p=0.25).
iPSCs and NE, but begin to show low expression in 2-week neural cell cultures (Figure 
2.2A, B) in both TT (blue) and CC (red) lines, and robust expression in 15-week neural 
cell cultures. However, expression of GABRA2 and GABRG1 shows differences 
between TT and CC lines starting in 2-week neural cell cultures (Figure 2.2C, D); 
expression in the TT lines progresses, but the CC lines show no expression for all time-
points. As epigenetic changes precede gene expression, and because we saw 
differences in expression levels as early as in 2-week neural cell cultures, we predicted 
that there could be different histone modification profiles for expresser and non-
expresser lines as early as at the neuroepithelial cell (NE) state. Knowing pluripotent 
cells (hESC lines H1 and H9, and iPSC line 6.9) have bivalent/poised promoters (see 
Figure 1.5), we set out to find when the switch from the poised promoter to a resolved 
active promoter occurs during differentiation. 
 First, to get a genome-wide perspective of H3K4me3 enrichment to see if there 
was reduction in H3K4me3 enrichment selectively in the chromosome 4p12 GABAA 
receptor subunit gene cluster in non-expresser lines, we performed ChIP followed by 
whole genome sequencing on iPSCs (one expresser and one non-expresser line) and 
neuroepithelial cells (one expresser and one non-expresser). A ChIP library was made 
using H3K4me3 IP DNA and input DNA and run on a NextSeq instrument. Analysis of 
the data was done using the program SICKLE first to trim low quality ends, STAR to 
align to the hg19 genome, and then Homer to create bedGraph files, obtain peak calls, 
annotate peaks, and create meta-gene profiles. Files were uploaded to the UCSC 
Genome Browser to visualize pile-up maps of the raw ChIP-seq data peaks and the 
peak calls. The distribution of peak calls is shown in Figure 2.3 for each line. Each pie  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Figure 2.2. mRNA expression time course of GABAA receptor subunit genes in expresser (TT)  (n=2) 
and non-expresser (C-carrier) (n=2) lines. (A) Expression of two genes, GABRA1 and GABRG2, 
located on chromosome 5q34. Both non-expresser and expresser lines show expression in neurons. 
(B) Expression of two genes, GABRA2 and GABRG1, located on chromosome 4p12. Expression 
begins in two week neurons in expresser lines, but non-expressers never express either gene up to 15 
week neurons.
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Figure 2.3. Distribution of H3K4me3 peaks from ChIP-seq. (A-D) Experimental lines. (E,F) 
Data from Genome Browser archive for comparison.
4%
4%
28%
15%
44%
6%
Exon Intron Intergenic
Promoter 5’ UTR Other
4%
7%
28%
18%
33%
11%
Exon Intron Intergenic
Promoter 5’ UTR Other
3%
7%
28%
13%
38%
10%
Exon Intron Intergenic
Promoter 5’ UTR Other
4%
7%
27%
15%
38%
10%
Exon Intron Intergenic
Promoter 5’ UTR Other
3%
7%
28%
11%
40%
10%
Exon Intron Intergenic
Promoter 5’ UTR Other
4%
7%
26%
15%
36%
12%
Exon Intron Intergenic
Promoter 5’ UTR Other
Expresser iPSC Expresser NE
Non-expresser iPSC Non-expresser NE
H1 ES iPSC 6.9
A B
C D
E F
chart shows the percentage of peaks within exons, introns, intergenic regions, 
promoters, 5’ UTRs, and an ‘other’ group for the remaining peaks. Archived data from 
the Genome Browser for H1 ES cells and iPSC 6.9 were analyzed to create pie charts 
to use as a comparison to our samples and show similar profiles indicating our ChIP-
seq was successful. Additionally, the distribution of alignments were nearly identical 
between samples. The meta-gene profile for each line is shown in Figure 2.4 showing 
similar distribution of ChIP-seq alignment along a meta-gene and a peak at the 
transcript start site. All genes are scaled to be 10,000bp (gene linear distance 
equivalent of 0% to 100%) with 5,000bp upstream and downstream of the gene (Figure 
2.4 A-D). Again, archived data from the Genome Browser for H1 ES cells and iPSC 6.9 
(Figure 2.4 E, F) were used for comparison and showed similar profiles to our samples, 
again validating our ChIP-seq protocol. 
 Pile-up maps of raw ChIP-seq data and the peak calls visualized in the UCSC 
genome browser show robust enrichment of H3K4me3 in a pluripotent-associated gene, 
NANOG, in both expresser and non-expresser iPSC lines, but as expected, not in the 
iPSC-derived neuroepithelial cells from either line (data not shown). In contrast, there 
was robust enrichment of H3K4me3 in a neuronal frontal cortex-associated gene, 
FOXG1, in the neuroepithelial cells, but not in the iPSCs (data not shown). These 
results further validate the ChIP-seq datasets. 
 At the GABRA2 promoter, there is enrichment of H3K4me3 in expresser iPSCs 
and iPSC-derived neuroepithelial cells, but not in the non-expresser neuroepithelial cells 
and unexpectedly also in the non-expresser iPSC sample (Figure 2.5). To see if this 
difference between expresser and non-expresser lines was present in the other  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Figure 2.4. Meta-gene profiles for (A) expresser iPSC, (B) expresser neuroepithelial cells, (C) non-
expresser iPSCs, and (D) non-expresser neuroepithelial cells. H1 (E) and iPSC 6.9 (F) were used for 
comparison. All genes are scaled to 10,000bp (equal to 100%) with 5,000bp upstream and downstream 
of the gene included.
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chromosome 4p12 GABAA receptor subunit genes, enrichment of H3K4me3 was 
examined in the promoters of GABRG1, GABRA4, and GABRB1 (Figure 2.6A-C). 
Similar to GABRA2, enrichment of H3K4me3 in expresser iPSCs and iPSC-derived 
neuroepithelial cells was significantly higher at these promoters than enrichment in non-
expresser iPSCs and iPSC-derived neuroepithelial cells. 
 We also assessed the flanking genes of the GABAA receptor subunit gene cluster 
on chromosome 4p12. GUF1, GNPDA2, and COMMD8 all showed robust expression in 
all lines (Figure 2.7A-C). 
 When comparing peak calls between GABAA receptor subunit gene clusters on 
different chromosomes, there were no significant differences between the expresser or 
the non-expresser line in these clusters as there was with the chromosome 4p12 cluster 
(data not shown). 
 To contrast peaks in the ChIP-seq data, the application DiffBind was used. The 
number of H3K4me3 binding regions in the four samples was 21,032. When contrasting 
samples by expresser and non-expresser lines, there were 46 regions that were 
significantly different at a false discovery rate (FDR) <0.01 including the four GABAA 
receptor subunit genes clustered at chromosome 4p12 (see Table 2.2 for full list). 
Contrasting iPSC and neuroepithelial cell samples, there were 5,960 significant 
differences found at a FDR <0.01 reflecting the large change in the enrichment 
distribution of this epigenetic mark associated with the differentiation process. 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Gene Name Gene Description Chromosome
ACOT1 acyl-CoA thioesterase 1 chr14
ANKRD20A5P ankyrin repeat domain 20 family, member A5, pseudogene chr18
BMS1P5 BMS1 pseudogene 5 chr10
CHCHD2 coiled-coil-helix-coiled-coil-helix domain containing 2 chr7
CNTNAP3 contactin associated protein-like 3 chr9
COL22A1 collagen, type XXII, alpha 1 chr8
CRYZ crystallin, zeta (quinone reductase) chr1
EIF3CL eukaryotic translation initiation factor 3, subunit C-like chr16
FAM86B3P family with sequence similarity 86, member A pseudogene chr8
GABRA2 gamma-aminobutyric acid (GABA) A receptor, alpha 2 chr4
GABRA4 gamma-aminobutyric acid (GABA) A receptor, alpha 4 chr4
GABRA5 gamma-aminobutyric acid (GABA) A receptor, alpha 5 chr15
GABRB1 gamma-aminobutyric acid (GABA) A receptor, beta 1 chr4
GABRG1 gamma-aminobutyric acid (GABA) A receptor, gamma 1 chr4
GRM7 glutamate receptor, metabotropic 7 chr3
HKR1 HKR1, GLI-Kruppel zinc finger family member chr19
HLA-C major histocompatibility complex, class I, C chr6
HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 chr6
HLA-DRB1 major histocompatibility complex, class II, DR beta 1 chr6
LINC01060 long intergenic non-protein coding RNA 1060 chr4
LINC01194 long intergenic non-protein coding RNA 1194 chr5
LOC100287846 patched 1 pseudogene chr8
LOC101927815 uncharacterized LOC101927815 chr8
LOC101927815 uncharacterized LOC101927815 chr8
LOC101927815 uncharacterized LOC101927815 chr8
LYNX1 Ly6/neurotoxin 1 chr8
NEUROD4 neuronal differentiation 4 chr12
NLRP2 NLR family, pyrin domain containing 2 chr19
NNAT neuronatin chr20
PARG poly (ADP-ribose) glycohydrolase chr10
PHACTR3 phosphatase and actin regulator 3 chr20
PHACTR3 phosphatase and actin regulator 3 chr20
PLS3 plastin 3 chrX
PNRC2 proline-rich nuclear receptor coactivator 2 chr1
SEPT7P9 septin 7 pseudogene 9 chr10
SLURP1 secreted LY6/PLAUR domain containing 1 chr8
SRSF10 serine/arginine-rich splicing factor 10 chr1
STAG3L2 stromal antigen 3-like 2 (pseudogene) chr7
THEM6 thioesterase superfamily member 6 chr8
TRIM43 tripartite motif containing 43 chr2
TRPC7 transient receptor potential cation channel, subfamily C, member chr5
TTTY3 testis-specific transcript, Y-linked 3 (non-protein coding) chrY
TULP1 tubby like protein 1 chr6
ZNF132 zinc finger protein 132 chr19
ZNF558 zinc finger protein 558 chr19
ZSCAN23 zinc finger and SCAN domain containing 23 chr6
Table 2.2. DiffBind regions significantly different at a false discovery rate (FDR) <0.01 
including the chromosome 4p12 GABAA receptor subunit genes (highlighted in orange).
Validating ChIP-seq with ChIP-PCR 
 ChIP-qPCR was first done in iPSCs to evaluate the presence or absence of a 
bivalent promoter state in our cell lines as the ChIP-seq data showed a lack of 
H3K4me3 enrichment in the non-expresser line. In these experiments, primers targeting 
the promoter of GABRA2 were used, primers targeting the promoter of GABRB2 were 
used to evaluate enrichment in a GABAA receptor subunit gene located on a different 
chromosome (chromosome 5), and primers targeting the promoter of GUF1, a flanking 
gene of the chromosome 4p12 GABAA receptor subunit gene cluster shown to have 
mRNA expression in both expresser and non-expresser lines. A negative control 
targeting a region within the GABRA2 gene lacking enrichment of H3K4me3 and 
H3K27me3 (based on archived ChIP-seq data (see Figure 1.5)) was also examined. 
After qPCR with the GABRA2 promoter region primers, we found that expresser iPSC 
lines showed robust enrichment of the active H3K4me3 mark and low, but present, 
enrichment of the repressive H3K27me3 mark (Figure 2.8A, B). However, the non-
expresser iPSC lines, while showing some enrichment of the repressive H3K27me3 
mark, showed significantly less enrichment of the active H3K4me3 mark compared to 
the expresser lines (Figure 2.8A, B) consistent with the ChIP-seq findings. This 
suggests that the promoter of the non-expresser cells was in fact never poised in iPSCs 
as there is a lack of H3K4me3 enrichment, and that the differences in mRNA expression 
fate between lines seen in neural cell cultures may be set not during neural 
differentiation, but in iPSCs. 
 To examine whether the differences seen between the iPSCs in the two 
expression groups were specific to the chromosome 4p12 GABAA receptor subunit  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Figure 2.8. Enrichment of histone modifications in expresser and non-expresser iPSCs. (A) 
H3K4me3 enrichment at the GABRA2 promoter (expresser n=7 and non-expresser n=4; **p=0.01). 
(B) H3K27me3 enrichment at the GABRA2 promoter (expresser n=7 and non-expresser n=4; 
p=0.24). (C) H3K4me3 enrichment at the GABRB2 promoter (expresser n=6 and non-expresser 
n=4; p=0.65). (D) H3K27me3 enrichment at the GABRB2 promoter (expresser n=5 and non-
expresser n=4; p=0.74). (E) H3K4me3 enrichment at the GUF1 promoter (expresser n=7 and non-
expresser n=3; p=0.83). (F) H3K27me3 enrichment at the GUF1 promoter (expresser n=7 and non-
expresser n=4; p=0.42).
gene cluster, we examined the promoter of GABRB2, a GABAA receptor subunit gene 
located on chromosome 5. Enrichment of H3K4me3 was robust in both expresser and 
non-expresser lines, with no significant difference between the two groups (Figure 
2.8C, D). In addition, H3K27me3 enrichment was robust in both groups indicating that 
this gene promoter is in a poised promoter state in iPSCs with no significant difference 
between expressers and non-expresser lines (Figure 2.8C, D). 
 As mentioned in Chapter 1, Lieberman et al. (2015) discovered that the genes 
flanking the chromosome 4p12 GABAA receptor subunit gene cluster were expressed in 
neural cell cultures derived from both expresser and non-expresser lines indicating that 
transcriptional repression in this region is localized to the GABAA receptor subunit gene 
cluster in non-expressers. Because of this, we evaluated the histone modification 
enrichment at the promoter of GUF1, a flanking gene downstream of GABRG1. This 
showed a strong promoter with high H3K4me3 enrichment, but no H3K27me3 
enrichment and with no difference seen between the expressers and non-expressers at 
this site (Figure 2.8E, F) consistent with the gene expression data (Lieberman, Kranzler 
et al. 2015). To measure background enrichment, a region within GABRA2 that was 
unenriched (based on the Genome Browser data in Figure 1.5) was used as a negative 
control. As expected, both H3K4me3 and H3K27me3 enrichment was very low in both 
expresser and non-expresser lines (Figure 2.9A, B). GAPDH was used as a positive 
control for H3K4me3 enrichment showing robust enrichment in both expressers and 
non-expressers (Figure 2.9C, D), and MYOD1 was used as a positive control for 
H3K27me3 enrichment showing robust enrichment in both expressers and non-
expressers (Figure 2.9E, F). 
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Figure 2.9. Enrichment of histone modifications in expresser and non-expresser iPSCs. (A) 
H3K4me3 enrichment at the GABRA2 unenriched negative control (expresser n=7 and non-
expresser n=4; p=0.68). (B) H3K27me3 enrichment at the GABRA2 unenriched negative control 
(expresser n=7 and non-expresser n=4; p=0.3). (C) H3K4me3 enrichment at the GAPDH promoter 
(expresser n=6 and non-expresser n=4; p=0.42). (D) H3K27me3 enrichment at the GAPDH 
promoter (expresser n=6 and non-expresser n=4; p=0.25). (E) H3K4me3 enrichment at the MYOD1 
promoter (expresser n=6 and non-expresser n=4; p=0.71). (F) H3K27me3 enrichment at the 
MYOD1 promoter (expresser n=5 and non-expresser n=4; p=0.52).
F
Discussion 
 Based on archived ChIP-seq data from the UCSC Genome Browser from H1 and 
H9 embryonic stem cell and iPSC 6.9 tracks (Figure 1.5) and the data from Ernst et al., 
2011, we expected to see a basal poised/bivalent H3K4me3 and H3K27me3 epigenetic 
state at the GABRA2 gene promoter in all iPSC lines followed by divergence of 
epigenetic marks reflecting gene expression status after beginning neural differentiation. 
However, we found that there is a difference in expresser and non-expresser lines 
already in iPSCs. While expresser lines showed enriched H3K4me3 and H3K27me3 
marks, the non-expresser lines showed significantly less enrichment of the H3K4me3 
mark, but showed similar levels of H3K27me3 enrichment as the expresser lines. 
 As there were significant differences of H3K4me3 enrichment between the 
expresser and non-expresser lines in the ChIP-seq experiments, it would be interesting 
to get a genome wide evaluation of H3K27me3 enrichment in expresser and non-
expresser iPSCs. It was hard to tell in the qPCR experiments if there was much 
H3K27me3 enrichment in the non-expresser lines and having this additional ChIP-seq 
data may help give a comprehensive view of H3K4me3 versus H3K27me3 
modifications in the chromosome 4p12 receptor subunit gene cluster region. 
Additionally, as mentioned in Chapter 1, the H3K27me3 mark is regulated by the 
polycomb repressive complex 2 (PRC2) and is normally associated with poised 
promoters and pluripotent cells. During differentiation if the gene is to be repressed, the 
H3K27me3 mark is replaced with H3K9me3, which is associated with gene repression 
in differentiated cells. It would be interesting to see if the non-expresser lines show 
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replacement of H3K27me3 with H3K9me3 in iPSCs or neuroepithelial cells in response 
to this yet-to-be identified functional variant. 
 The limited H3K4me3 enrichment in the GABRA2 promoter in the non-expresser 
iPSC lines observed in our ChIP-seq and ChIP-qPCR datasets suggests that epigenetic 
reprogramming during iPSC generation is targeting the chromosome 4p12 receptor 
subunit gene cluster for inhibition in non-expresser lines. It is possible that this region in 
non-expressers acquires another repressive epigenetic mark that is impacting the ability 
of H3K4 methyltransferases to methylate K4. Another possibility, discussed in Chapter 
3, is that there is differential DNA methylation at the CpG islands in the promoters of the 
chromosome 4p12 GABAA receptor subunit genes between expresser and non-
expresser lines and this is inhibiting transcription activation. 
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Chapter 3. 
DNA Methylation of GABAA Receptor Subunit Genes 
Background 
 DNA methylation is a common epigenetic modification that can be altered when 
reprogramming fibroblasts to iPSCs. It is also known that there is a strong relationship 
between DNA methylation and histone modifications. In early development, CpG islands 
are typically unmethylated. This is perhaps due to the presence of methylation of the 
lysine 4 residue on the H3 tail (H3K4me). DNMT3L, a catalytically inactive binding 
partner of DNMT3A2 and DNMT3B, initiates the interaction between chromatin and the 
DNMT complex. It does this by recognizing the K4 residue on the H3 subunit tail. 
However, when H3K4 is methylated, it blocks the ability for DNMTL to bind inhibiting 
DNA methylation at this site. Thus, there is a negative correlation between methylation 
of H3K4 (associated with activation of genes) and DNA methylation of CpG islands 
(associated with gene repression). In addition, DNA methylation has been linked to 
H3K27me3, a mark associated with gene repression. It has been suggested that DNA 
methylation of CpG islands at promoters during differentiation is more likely if the 
promoter is marked with H3K27me3 in embryonic stem cells (Cedar and Bergman 
2009, Rose and Klose 2014). 
 A study done in Bulgaria looking at genome-wide methylation profiles in 
schizophrenia found DNA hypermethylation of the CpG island in the GABRA2 promoter 
in male schizophrenic subjects (Rukova, Staneva et al. 2014). In addition, a study 
looking at DNA methylation in aging, a progressive increase in DNA methylation of the 
 49
GABRA2 CpG island over the lifespan was observed in men (Siegmund, Connor et al. 
2007). These studies suggest that differential DNA methylation of the GABRA2 
promoter CpG island could be a possible explanation for the two gene expression 
phenotypes we observe. Based on these studies and the ChIP findings in Chapter 2, we 
set out to evaluate a possible link between reprogramming fibroblasts into iPSCs and 
DNA methylation states of the GABRA2 promoter CpG island, as well as the link to 
chromosome 4p12 GABAA receptor subunit gene cluster expression status. We 
hypothesize that the fibroblast cells will have DNA methylation present at the GABRA2 
promoter CpG island which are reset to an unmethylated state in GABAA receptor 
subunit gene cluster expresser lines but remain methylated in non-expresser lines. 
Methods 
Cell lines 
 Lines were the same as used in the 2015 Lieberman study (Lieberman, Kranzler 
et al. 2015). Briefly, skin punch biopsies were taken from 21 patients and were used to 
generate fibroblast cell lines. Fibroblasts were reprogrammed into induced pluripotent 
stem cells (iPSCs) by the Stem Cell Core at the University of Connecticut Health 
Center. This study utilized 24 expresser lines from 17 subjects and 15 non-expresser 
lines from 11 subjects to measure DNA methylation at the CpG island in GABRA2. For 
targeting GABRA4 promoter CpG island DNA methylation, eight expresser lines lines 
from six subjects, and seven non-expresser lines from seven subjects were examined. 
For GABRB1, five expresser lines from four subjects, and five non-expresser lines from 
five subjects were examined. A gene flanking the GABAA receptor subunit gene cluster, 
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GNPDA2, whose RNA levels are not linked to the cluster expression pattern, was 
examined using two expresser lines from two subjects and three non-expresser lines 
from three subjects. 
DNA methylation assay 
 Evaluation of DNA methylation was done using a combination of the method in 
Holemon et al. (Holemon, Korshunova et al. 2007) and the Qiagen Epitect Methyl-qPCR 
protocol. Briefly, 250ng of fibroblast, or iPSC DNA was split into four tubes: mock-
enzyme (Mo), a CpG methylation sensitive (Ms) enzyme, HhaI  (New England 
Biosystems), a CpG methylation dependent (Md) enzyme McrBC (New England 
Biosystems), and a double enzyme mix with both HhaI and McrBC (Msd). Samples 
were incubated overnight at 37˚C. Digested DNA was then analyzed by qPCR using 
primers for a site within the GABRA2 promoter CpG island (Figure 3.1) using the RT2 
SYBR Green ROX qPCR Mastermix (Qiagen), a master mix designed for high GC 
content products. In addition, primer sets were designed for a site within the CpG 
islands in the promoters of GABRA4, GABRB1, and GNPDA2 (Table 3.1). The qPCR 
amplification protocol was 95˚C for 10 minutes, 3 cycles of 99˚C for 30 seconds and 
72˚C for 1 minute, and 40 cycles of 97˚C for 15 seconds and 72˚C for 1 minute. A 
dissociation curve was included at the end of the protocol to monitor melting curves for 
single melt peaks. Resulting Ct values for Mo, Ms, Md, and Msd were then entered into 
an Excel spreadsheet (www.sabiosciences.com/dna_methylation_data_analysis.php), 
that calculates digestion efficiency by giving an analytical window (W) and the 
percentage of DNA refractory (R) to restriction enzyme digestion, and also the  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Table 3.1. Primer sequences for DNA methylation studies.
Primer Target Sequence (5'-3') Tm (˚C)
 GA2CpG Forward v2 CpG island in the 
promoter of GABRA2
CTCGATCCCTCGATCCCTGGTAACT 61.2
 GA2CpG Reverse v2 CGCCACACTACATTCCCGGCTTTA 61.3
GA4CpG Forward v3 CpG island in the 
promoter of GABRA4
CAGGGTGCGAGGAGAGGGC 63.1
GA4CpG Reverse v3 ACGAAAGGGTGTGGAGCGGT 61.7
GB1CpG Forward v2 CpG island in the 
promoter of GABRB1
TCTGCGTTTCATTGGCGGTCAC 60.5
GB1CpG Reverse v2 GGCAGGGCCTTGGTGCAT 61.7
GNPDA2CpG Forward CpG island in the 
promoter of GNPDA2
GGCGTCCCAGTCTCAGCACAAA 62
GNPDA2CpG Reverse CGGTTCCTTCCTGCGCCTTTATCT 61.2
percentage of unmethylated DNA and methylated DNA using the following equations, 
where F is the fraction of DNA evaluated: 
DNA refractory to enzyme digestion: 
Unmethylated DNA: 
Hypermethylated DNA: 
Intermediately methylated DNA: 
Percentages were averaged among groups, standard error was calculated, and a 
Student’s T-test was used to analyze significance between the percentage of total 
methylation between groups. 
Results 
 De novo DNA methylation of the CpG island of the GABRA2 promoter has been 
shown to occur in both schizophrenia and aging (Siegmund, Connor et al. 2007, 
Rukova, Staneva et al. 2014), possibly suggesting that DNA methylation at this locus 
can vary based on genetic variation and developmental processes. To evaluate the 
possible presence of DNA methylation at the GABRA2 promoter, we used a DNA 
methylation assay which uses a methylation sensitive enzyme (HhaI), a methylation 
dependent enzyme (McrBC), and a double digest with both enzymes (see methods for 
further explanation). Digestion is followed by qPCR and Ct values are used to calculate 
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the percentage of unmethylated and methylated DNA. For example, if the target region 
is methylated, the Ms digest will result in little to no degradation of template resulting in 
qPCR Ct values equal to the mock digest, while the majority of the template will be cut 
by the Md enzyme resulting in an increase in Ct value. 
 We first examined fibroblast DNAs to evaluate CpG methylation status at the 
GABRA2 promoter CpG island site. We had hypothesized that non-expresser 
fibroblasts possessed DNA methylation at the GABRA2 promoter and that this was 
potentially maintained during the reprogramming process. Unexpectedly, we found that 
in dermal fibroblasts the GABRA2 promoter CpG island was unmethylated in all lines 
tested, regardless of GABRA2 tag-SNP genotype or expression phenotype (Figure 
3.2A). After the reprogramming process, iPSC clones generated from the same 
fibroblasts became differentially methylated (Figure 3.2B, the two iPSC clones color-
coded to parental fibroblast strain) indicating that reprogramming was inducing DNA 
methylation at this site, and that the level of methylation could differ between individual 
iPSC clones generated from the same fibroblast line. Further, there were discordant 
iPSC clones from the same parental fibroblasts. One such example is the CC line 703 
(pink dots), which gave rise to one CpG hypermethylated clone and one unmethylated 
clone. Discordance among clones was also seen in chromosome 4p12 GABAA receptor 
subunit gene expression status in iPSC-derived neurons (Lieberman, Kranzler et al. 
2015). 
 While the sample size in Figure 3.2B is small, there is a noticeable difference 
between TT lines, where only one of six clones shows greater than 80% CpG 
methylation at this site, and C-carrier lines where six out of eight have greater than 80%  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Figure 3.2. DNA methylation at the CpG island in the GABRA2 promoter. (A) DNA methylation in 
fibroblasts in all three GABRA2 rs279858 genotypes. Fibroblasts give rise to both expresser and non-
expresser iPSC lines. (B) Two iPSC lines generated from each of the fibroblasts from A. Graph shows 
varying levels of DNA methylation at the GABRA2 CpG island among clones from the same fibroblast 
line. Parental fibroblasts are color coded to their resulting iPSC clones.
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methylation at this site. This suggests that there is potentially some relation of CpG 
methylation to genotype. To evaluate the potential difference between expresser and 
non-expresser lines, 24 expresser lines and 16 non-expresser lines were analyzed. 
From this, we found that GABRA2 promoter CpG island methylation was greater in 
iPSC lines whose neural products were non-expressers, compared with expresser iPSC 
lines (Figure 3.3) (75% vs. 43%, respectively; *p=0.02). 
 To see if this difference in DNA methylation between expresser and non-
expresser lines was specific to the GABRA2 CpG island, or might be present for other 
GABAA receptor subunit genes on chromosome 4p12, we also examined sites within 
the CpG islands of the GABRA4 and GABRB1 promoters. The GABRG1 promoter does 
not contain an annotated CpG island and therefore was not examined. Similar to 
GABRA2, non-expresser lines showed more DNA methylation at the CpG islands in 
both the GABRA4 (**p=0.01) and GABRB1 (***p=0.003) promoters (Figure 3.4A, B). 
Based on the histone modification data in Chapter 2 and the gene expression data 
published in Lieberman et al 2015, we predicted that this variation in CpG methylation 
would be localized to the GABAA cluster genes so we targeted a site in the CpG island 
in the promoter of a flanking gene, GNPDA2. We observed low levels of methylation for 
GNPDA2 (Figure 3.4C); 0.04% +/- 0.01% expresser (n=2); 16.83% +/- 16.59% non-
expresser (n=3) and no significant difference between expressers and non-expresser 
lines (p=0.4) at this site suggesting that this difference in DNA methylation is specific to 
the GABAA receptor subunit gene cluster on chromosome 4p12. 
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Figure 3.3. DNA methylation in iPSCs targeting a site in the CpG island in the promoter of GABRA2. 
Non-expresser lines had significantly more DNA methylation than expresser lines (expresser n=24 
and non-expresser n=16; *p=0.02).
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Figure 3.4. DNA methylation in expresser and non-expresser iPSCs. Percent DNA methylation at sites 
within the CpG island in the GABRA4 promoter (expresser n=8 and non-expresser n=7; **p=0.01) (A), 
the CpG island in the GABRB1 promoter (expresser n=5 and non-expresser n=5; ***p=0.003) (B), and 
the CpG island in the promoter of a flanking gene of the GABAA receptor subunit gene cluster, GNPDA2 
(expresser n=2 and non-expresser n=3; p=0.42) (C).  
Discussion 
 It is known that the reprogramming process can result in aberrant side effects 
including changes in DNA methylation that are probably intrinsic to correct 
reprogramming (Lister, Pelizzola et al. 2011, Liang and Zhang 2013). However, for the 
lines evaluated in this thesis, this does not seem to be a random phenomenon. We 
found that DNA methylation at the GABRA2 gene promoter in iPSCs is significantly 
related to the future chromosome 4p12 GABAA receptor subunit gene cluster 
expression status in neural cells. It is possible that the DNA methylation differences 
dissipate after sufficient passages; however, there were no noticeable changes in 
methylation of lines in early passages versus the same lines at later passages (data not 
shown). In addition, preliminary studies with neuroepithelial cells show maintenance of 
the DNA methylation status reflecting the iPSC line used (data not shown). 
 One thing we do not know, however, is whether the DNA methylation we are 
seeing in the lines is coming from the AUD risk C-allele, the T-allele, or both. Allelic 
discrimination assays done in Lieberman et al. 2015 looking at SNPs in GABRG1, 
GABRA4, and GABRB1 suggest there is some allelic bias in gene expression in this 
region. This could mean there is also bias in DNA methylation, especially since DNA 
methylation is related to gene expression, or rather, repression. 
 A possible explanation of this increased DNA methylation at the GABRA2 CpG 
island in non-expresser lines could be that the functional variant(s) associated with the 
tag-SNP rs279858 cause an increase in DNMT3A/B activity causing de novo DNA 
methylation. Because only one amplicon at each CpG island was evaluated, it is 
unknown if this is specific to the chromosome 4 GABAA receptor subunit gene cluster or 
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if there is a more global phenomenon in these lines. To test this, full genome 
sequencing after a methyl-ChIP pull-down could be used to examine this. 
 Another interesting point with these findings is that while we saw methylation 
differences between expressers and non-expressers, when the methylation data were 
grouped according to rs279858 genotype, there was a trend, but no significant 
differences (data not shown). This would suggest that the initial DNA methylation 
generated during reprogramming is random with respect to rs279858 tag-haplotype, but 
that the maintenance of the DNA methylation states may be biased toward the loss of 
methylation during neural differentiation in rs297858 TT lines and maintenance of 
GABRA2 CpG methylation in CC lines. This would predict an association of methylation 
with genotype in neural cells, which had previously been associated with expression 
phenotype. 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Chapter 4. 
Discussion and Future Directions 
Discussion 
 Chapter 1 presented an interesting phenotype seen when studying an AUD 
associated SNP in the GABRA2 gene using iPSC-derived neural cell cultures. 
Lieberman et al., 2015, showed that lines derived from subjects carrying the rs279858 
AUD risk C-allele showed decreased expression of a cluster of GABAA receptor subunit 
genes on chromosome 4p12; GABRG1, GABRA2, GABRA4, and GABRB1 were 
termed “non-expresser” lines. They also found that the flanking genes of this cluster 
were expressed in both expresser and non-expresser lines. Because this phenotype 
was seen exclusively in this cluster of GABAA receptor subunit genes on chromosome 
4p12, we hypothesized that they share a common epigenetic regulatory element. 
 In Chapter 2, we explored the idea that the cluster of GABAA receptor subunit 
genes on chromosome 4p12 was being regulated by changes in histone modifications 
within this region. We looked at two modifications, one associated with active chromatin, 
H3K4me3, and one associated with transcriptional repression, H3K27me3. Using ChIP 
followed by genome-wide sequencing and qPCR, we found significant differences 
between expresser and non-expresser lines not only in iPSC-derived neurons, but also, 
and perhaps unexpectedly, in iPSCs. While previous ChIP-seq data from the UCSC 
Genome Browser indicated a poised promoter in iPSCs and ES cells, we did not see 
expression of the H3K4me3 mark in non-expresser lines indicating not a poised gene, 
but a repressed one. 
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 There is a known correlative relationship between the H3K27me3 mark and DNA 
methylation as they are both marks for repression, and a known inverse relationship 
between the H3K4me3 mark and CpG island DNA methylation (Cedar and Bergman 
2009). In Chapter 3, we set out to elucidate possible differences in DNA methylation at 
CpG islands in the promoters of the GABAA receptor subunit genes on chromosome 
4p12. We found that non-expresser lines showed significantly higher average DNA 
methylation compared to expresser lines, which were largely unmethylated. Only five of 
24 lines were >80% methylated in expresser lines versus 11 of 16 in the non-expresser 
lines. The fact that we see not only a reduction in H3K4me3 enrichment in non-
expresser lines, but also increased DNA methylation of the GABAA receptor subunit 
gene CpG islands, is consistent with the idea that histone methylation of H3K4 inhibits 
DNA methylation at CpG islands. 
 During differentiation, when promoters change from a poised state and begin to 
shift to either an active promoter or repressed, there can also be changes in the types of 
histone modifications present. The repressive H3K27me3 mark is common in pluripotent 
cells and is common in development, whereas the repressive H3K9me3 mark is 
associated with differentiated cells and is a more stable repressive mark. One possibility 
is that the H3K27me3 mark has been replaced by the H3K9me3 mark in the non-
expresser lines so we are missing a key repressive mark, which will be looked at in 
future studies. 
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Future Directions 
 An alternative regulatory mechanism not explored in this research may involve 
the rs279858 SNP itself. This synonymous SNP changes a TTT-lysine into a TTC-
lysine, with virtually no codon preference in humans. While previously thought of as 
“silent mutations,” GWAS studies have consistently shown synonymous SNPs 
correlated to many illnesses (Plotkin and Kudla 2011). Though there is no real codon 
preference here, the reason for this expresser versus non-expresser phenotype could 
be linked to the change in codon itself. Changing the codon has been shown to adjust 
the mRNA structure, potentially leaving it less or more stable as a result, thus affecting 
protein generation, or protein structure and folding (Plotkin and Kudla 2011). However, 
based on our findings here, it would seem that this is not the case. It seems that there is 
in fact a functional variant yet to be discovered that is influencing the creation of histone 
modification profiles and DNA methylation in iPSCs. 
 While expresser and non-expresser status has been linked to rs279858 genotype 
as reported in Lieberman et al. 2015, there are outliers present. The trend is that TT 
homozygotes are expressers and that C-carriers are non-expressers. However, there 
are cases where a CT or CC subject can produce both an expresser line and a non-
expresser line. In addition there are two TT subjects which produce non-expresser iPSC 
lines. This suggests that we are close to the functional variant, but that it is not directly 
linked to rs279858 genotype. However, using the tag-SNP rs279858 as a marker that 
we see is linked to epigenetic features like DNA methylation of CpG islands, we can use 
this SNP and this assay to screen additional lines in the future. 
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 In addition, the findings in this study could be relevant on a greater scope. If we 
are seeing such a dramatic phenotype in iPSC lines with different genotypes at this one 
SNP, it is possible similar phenotypes exist in iPSCs from other illnesses. It is possible 
that other SNPs associated with other illnesses are also somehow indirectly influencing 
DNA methylation of CpG islands, or histone modifications as were associated with the 
rs279858 genotype. 
 Considering the fact that we see such a strong phenotype in iPSCs and in the 
early development of neurons, the effects that this phenotype might have in the 
developing brain are of interest. Perhaps this phenotype only occurs in regions linked to 
AUDs such as the frontal cortex and the reward pathway including the ventral tegmental 
area and the nucleus accumbens. This would lead to a change in the normal pattern of 
GABAA subunit utilization within these regions with different electrophysiological 
characteristics and subtle variation and result in the disruption of  these neuronal 
systems. 
Long distance chromatin looping 
 Another possible epigenetic feature is long distance chromatin looping. In 
addition to transcription factors binding promoters of genes, chromatin can also be 
looped bringing a regulatory element, such as an enhancer, into close proximity to a 
promoter affecting overall transcriptional output of the gene. A common protein that 
initiates long distance chromatin looping is the CCCTC-binding factor (CTCF), a 11-zinc 
finger protein. CTCF binds a specific sequence in the genome, CCCTC, and with the 
help of cohesin (DeMare, Leng et al. 2013, Merkenschlager and Odom 2013), CTCF 
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proteins can loop together bringing distant regulatory elements, such as enhancers, in 
close contact with promoters creating an active chromatin hub. This leads to higher 
levels of transcription (Figure 4.1; adapted from (Stadhouders, Thongjuea et al. 2012)). 
Based on ChIP-seq data (from the UCSC Genome Browser) done with an antibody to 
CTCF in iPSCs, there are multiple CTCF sites in and around the GABAA receptor 
subunit gene cluster on chromosome 4p12. One way to look at the 3D structure of these 
loops, and to see which sites interact with which, is to use Chromatin Conformation 
Capture (3C). This process involves crosslinking cells, digesting the DNA, ligating the 
ends together, and reverse crosslinking. The products are then detected by PCR, and 
the quantified products are mapped to the genome and interactions can be visualized 
based on a known anchor site to other distant sites (Naumova, Smith et al. 2012). A 
variation of this called Chromatin Interaction Analysis by Paired-End Tag sequencing, or 
ChIA-PET, uses this technique combined with immunoprecipitation. For example, 
studies done by Ruan et al., (2012) as part of the ENCODE project, used ChIA-PET in 
K562 cells to visualize long-distance chromatin looping between CTCF sites. The data 
from these studies indicate a possible loop encompassing the chromosome 4p12 
GABAA receptor subunit gene cluster (Figure 4.2). It is possible that the functional 
SNP(s) linked to the tag-SNP rs279858 change an anchor point or distal point for long 
distance chromatin looping. 
Targeted resequencing 
 The goal of this research is to aid in finding the functional genetic variant(s) 
within the GABRA2 haplotype block associated with AUDs. In order to do so, our lab 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Low levels of 
transcription
Increased levels of transcription
CTCF Enhancer Cohesin mRNA
Figure 4.1. CTCF looping. CTCF binds a specific sequence in the genome and with the help of cohesin, 
CTCF proteins loop together bringing elements, such as enhancers, in close contact of promoters 
creating an active chromatin hub. This leads to higher levels of transcription (Figure adapted from 
Stadhouders, Thongjuea et al., 2012). 
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has done some targeted resequencing of the 140kb haplotype block using the Haloplex 
system. We looked at three TT and three CC expressers, and one TT and two CC non-
expressers. While we did not find any SNPs associated with expression status stronger 
than the tag-SNP rs279858, we did find 224 SNPs in linkage disequilibrium with 
rs279858. In addition, we found a ~2kb deletion in the intergenic region between 
GABRA2 and GABRG1 in TT subjects, regardless of chromosome 4p12 GABAA 
receptor subunit gene cluster expression status (Figure 4.3). Data from the 1000 
Genomes Project shows this deletion present in approximately 47% of Caucasian 
chromosomes. It is possible that CC subjects, which do not have this ~2kb deletion, 
have a sequence within this region prone to altering regional epigenetics, which 
ultimately influences the expression of the chromosome 4p12 GABAA receptor subunit 
genes. In fact, there is a THE1B long terminal repeat (LTR) sequence within this 
deletion, which has previously been shown to activate the proto-oncogene CSF1R in 
human lymphoma cells (Lamprecht, Walter et al. 2010). The activation of this LTR could 
potentially be recruiting DNMTs to this region of the genome, or be inhibiting methylation 
of H3K4 in non-expresser lines during neural differentiation. 
 Intriguingly, the frequency of this deletion is seen far less in African Americans, 
affecting only 22% of chromosomes and is not linked to rs279858, making these 
subjects an asset to finding the possible functional variant in this haplotype block. We 
have obtained ten African American fibroblast lines and genotyped them (Table 4.1). 
There is one line of particular interest as it is homozygous for TT at the rs279858 
genotype. As mentioned above, Caucasian lines homozygous for TT also contain a 
~2kb deletion in the intergenic region between GABRA2 and GABRG1, this line,  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Figure 4.3. Targeted resequencing pile-up data of the region spanning the 140kb haplotype block (3’ 
end of GABRA2 and the intergenic region between GABRA2 and GABRG1. TT lines show a 2kb 
deletion in this region, regardless of expression status. 
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Line rs279858 2kb INDEL 
CD2 CT DEL/INS 
CD3 TT INS/INS 
CD4 CT INS/INS 
CD5 CT INS/INS 
AG14298 CT DEL/INS 
GM03349C TT DEL/INS 
AG09699 TT DEL/DEL 
AG09555 TT DEL/DEL 
AG09150B TT DEL/DEL 
GM05757C CT DEL/INS 
Table 4.1. African-American fibroblast lines with corresponding rs279858 genotype and the presence of 
a 2kb insertion/deletion in the intergenic region between GABRA2 and GABRG1. The highlighted line is 
of particular interest.
however, does not have this deletion (highlighted line in Table 4.1). These lines will be 
reprogrammed into iPSCs by the UConn Stem Cell Core, and future studies will look at 
the histone modification profiles and DNA methylation pattern at CpG islands of these 
lines, and mRNA expression of GABAA receptor subunits genes will be measured in 
iPSC-derived neurons. 
Targeted editing with CRISPR/Cas9 
 The clustered regularly interspaced short palindromic repeats (CRISPR) and the 
CRISPR associated protein 9 (Cas9) (CRISPR/Cas9) system is based on an adaptive 
immune response against microphages in prokaryotes and is the newest genome 
editing tool first used in mammalian cells in 2013 (Hsu, Lander et al. 2014). A single 
guide RNA (sgRNA), composed of a CRISPR RNA (cRNA) fused to a trans-activating 
cRNA (tracrRNA) can be engineered to target a specific sequence in the genome where 
the Cas9 nuclease creates a double-stranded break allowing the genome to be edited 
at this site (Ceasar, Rajan et al. 2016). By utilizing this technology, it is possible to 
efficiently target and modify genetic mutations that cause disease. For example, when 
we discover candidates for the functional variant linked to our tag-SNP rs279858, we 
can use the CRISPR/Cas9 system to target and edit this variation in non-expresser 
lines to create isogenic versions of the previously deemed ‘non-expresser’ lines. By 
doing this, we should see changes in DNA methylation and histone modification 
enrichment at the promoters of the chromosome 4p12 GABAA receptor subunit gene 
cluster in iPSCs, and gene expression of the chromosome 4p12 GABAA receptor 
subunit gene cluster in neurons. 
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 Alternatively, we could use the CRISPR/Cas9 system to find the functional 
variant. As mentioned above, our targeted resequencing of the 140kb haplotype block 
uncovered a 2kb deletion seen in the TT lines, regardless of expression status, that the 
CC lines did not possess. It was also mentioned that there is a THE1B sequence within 
this sequence that could potentially be creating the expresser and non-expresser lines. 
We could use CRISPR/Cas9 to target and this sequence in CC lines to see if DNA 
methylation decreases, histone modification enrichment at the promoters of the 
chromosome 4p12 GABAA receptor subunit gene cluster increases in iPSCs, and gene 
expression of the chromosome 4p12 GABAA receptor subunit gene cluster in neurons is 
restored. 
Allelic imbalance  
 While once thought to be limited to X-linked and imprinted genes, recent studies 
have found that many autosomal genes also show monoallelic expression (Nag, Savova 
et al. 2013). In the recent publication from the lab, Lieberman et al., 2015, showed 
allelic imbalance in a subset of lines looking at iPSC-derived neural culture cDNA at 
SNPs in genes nearby rs279858 (Lieberman, Kranzler et al. 2015). 
 We found a SNP located in a H3K4me3 enriched region of the GABRA4 
promoter, rs2229940. In a preliminary experiment, we used a TaqMan genotype assay 
targeting this SNP with ChIP DNA from H3K4me3 and H3K27me3 immunoprecipitations 
to look at the presence of allelic imbalance of histone modification enrichment in this 
GABAA receptor subunit gene cluster. Though inconclusive, preliminary results suggest 
the presence of possible allelic bias suggesting there is random event that shows allelic 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preference during reprogramming, that is possibly influenced by a functional variant in 
the 140kb haplotype block. 
 In addition to possible allelic bias of histone modifications, it is also unknown if 
the DNA methylation we are seeing is coming from only one allele, or a combination of 
the two. Using digested DNA from the DNA methylation assays, allelic imbalance assay 
can be done to assess allelic imbalance of DNA methylation in fibroblasts and iPSCs. 
  
Comparing iPSCs to hESCs 
 We found a significant difference in DNA methylation at the CpG island in the 
GABRA2 promoter depending on rs279858 genotype. An interesting experiment would 
be to look at DNA methylation at the CpG island in the GABRA2 promoter as well as 
H3K4me3 and H3K27me3 enrichment in human embryonic stem cell (ESC) lines. 
Looking at hESC lines would shed light on whether what we are seeing in iPSCs is an 
actual developmental difference linked to rs279858 genotype, or an effect of 
reprogramming skin cell fibroblasts into iPSCs. Preliminary data in our lab has looked at 
DNA methylation at the GABRA2 CpG island in five ESC lines. Among the lines were 
H1 (CC genotype), H9 (TT), CT2 (TT), CT3 (CT), and CT4 (TT). While the sample size 
was small, we saw no significant correlation to rs279858 genotype to DNA methylation, 
as most lines, regardless of genotype were unmethylated. This would suggest that what 
we are seeing in the iPSC lines is due to an event occurring during the reprogramming 
process. It is known that many aberrant effects can take place during reprogramming, 
such as random mutations, DNA methylation, and changes in histone modification 
profiles. However, even if what we are seeing is a reprogramming side effect, we have 
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shown that it is significantly related to rs279858 genotype indicating some link between 
genotype and epigenetic regulation. Further studies should be done to look at more 
hESC lines to see if this is a pluripotent stem cell phenomenon, or a reprogramming 
artifact cued by the functional variant linked to the rs279858 genotype. 
  
Working model 
 The findings in this thesis have provided insights into the epigenetic factors 
affecting gene expression in iPSC-derived neural cultures from lines with different 
rs279858 genotypes. Based on these findings, we have established a working model 
(Figure 4.4). This model suggests that fibroblasts with different rs279858 genotypes 
have no epigenetic differences between lines. However, during the reprogramming 
process, placement of H3K4me3 marks and de novo DNA methylation at the CpG 
islands of the chromosome 4p12 GABAA receptor subunit gene cluster differs creating 
expresser lines and non-expresser lines. As mentioned in Chapter 3 discussion, there 
were no significant differences in the amount of DNA methylation between genotypes, 
but there were significant differences between expressers and non-expressers. This 
could indicate that the initial DNA methylation during reprogramming is random, but the 
maintenance of this methylation could differ between genotypes. The absence of 
H3K4me3 in non-expresser lines also provides an opportunity for the CpG islands in 
this region to be methylated. Then when iPSCs are differentiated into neurons, the DNA 
methylation resolves and is either present (in non-expresser lines) or absent (in 
expresser lines). 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Fibroblasts
iPSCs
Neurons
Expressers
11/16 >80% methylation 
No H3K4me3 enrichment
No DNA Methylation 
No H3K4me3 enrichment
5/24 >80% methylation 
H3K4me3 enrichment
Non-expressers
?    0/24  >80% methylation 
H3K4me3 enrichment 
TT associated
?    16/16  >80% methylation 
No H3K4me3 enrichment 
C-Carrier associated
Figure 4.4. Working model.
DNMT recruitment?
 Our revised hypothesis is that the yet-to-be-identified functional variant inhibits 
long distance chromatin looping, inhibits H3K4 methylation, and/or recruits DNMT3A 
and DNMT3B for de novo DNA methylation, resulting in repression of this region. 
Conclusion 
 This research provides a small entrée into understanding the epigenetic changes 
seen in iPSCs after reprogramming and how they may regulate and affect gene 
expression in later development, especially as it relates to AUDs. Research models are 
never perfect or completely applicable, and the use of iPSCs in researching 
neurological illnesses certainly has its limitations. However, IPSCs and iPSC-derived 
neurons have provided a new unparalleled way to study neurological illnesses. They 
have given us access to live human neurons and allowed us to study the 
electrophysiological, morphological, and molecular phenotypes previously unknown. 
Now that we have the tools to study AUDs at a cellular and molecular level, we can 
focus on more specific elements of why certain SNPs increase the risk of developing an 
AUD. 
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